Chondroblastoma's Lung Metastases Treated with Denosumab in Pediatric Patient

Cancer Res Treat. 2021 Jan;53(1):279-282. doi: 10.4143/crt.2020.384. Epub 2020 Aug 6.

Abstract

Chondroblastoma is a rare benign chondrogenic tumor that occurs in skeletally immature patients between ages 10 and 20 years old. In literature are reported few cases of lung metastases, mainly occurred after surgery or local recurrences. There is no evidence on the pathogenesis of lung metastasis, as well as pulmonary disease course. Few treatments for metastases with aggressive behavior were based on chemotherapy regimen employed in other sarcoma with no results or not satisfying ones. Denosumab is approved for treatment of giant cell tumors and it is under investigation for other giant cell-rich bone tumors. Here, we report a case of a 16-year-old male chondroblastoma of the left humerus with bilateral lung metastases at presentation and progressing during follow-up, treated with denosumab for almost 2 years. We confirm that denosumab treatment can be effective in controlling chondroblastoma metastasis and it has been a safe procedure in an adolescent patient.

Keywords: Chemotherapy; Chondroblastoma; Denosumab; Lung; Metastasis; Pediatrics.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use*
  • Chondroblastoma
  • Denosumab / pharmacology
  • Denosumab / therapeutic use*
  • Humans
  • Lung Neoplasms
  • Male
  • Neoplasm Metastasis

Substances

  • Bone Density Conservation Agents
  • Denosumab